Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in
Closed
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverBLCO
HealthcareNYQUSD

Bausch + Lomb Corporation

$0012345678900123456789.0012345678900123456789-0.3%
52w low $13.77$18.92 52w high
Market data · updated 5h ago
Market data
Market cap
$5.70B
52w range
$13.77 - $18.92
Beta
0.56
Sector
Healthcare
Data quality
83/100
Valuation
fair value estimate
$17.90
Margin of safety
+5.7%
Forward P/E
14.9x
PEG ratio
0.89
Quality & efficiency
Moat score
46/100
Return on equity
-3.3%
Profit margin
-4.2%
Debt / equity
0.79
Growth & analysts
Revenue growth
+9.4%
Analyst target
$18.14
Target upside
+7.1%
Analysts
11
Run the 10-point checklist before you buy How these numbers are made

About Bausch + Lomb Corporation

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Valuation

ValueGrowthProfitHealthIncome34QUALITY
Overall Rating
52
Moderate quality
Moderate quality

Derived from filed metrics · High confidence (83% of the inputs available)

Moat Score46
Fair value estimate
$17.90+5.7% upside

Moat, fair value and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
$5.70B
P/E Ratio
N/A
Dividend Yield
0.00%
Revenue Growth
+9.4%
Profit Margin
-4.2%
ROE
-3.3%
Debt / Equity
0.79
Beta
0.56

Statistics

Similar Stocks · Healthcare

Latest News · BLCO